XPG rs873601位点多态对肺癌铂类药物化疗疗效影响的研究  

The effect of XPG gene polymorphism on the efficacy of chemotherapy for lung cancer platinum drugs

作　　者：邝仕成 王苏丹 朱瑞楠 吕鹏飞[3] 肖莎 Kuang Shicheng;Wang Sudan;Zhu Ruinan(The First Affiliated Hospital of Hainan Medical University,Haikou 570311;School of Public Health,Hainan Medical University,Haikou 571199)

机构地区：[1]海南省人民医院,海南医学院附属海南医院药学部,海口570311 [2]海南医学院公共卫生学院环境卫生与职业医学教研室,海口571199 [3]海南医学院第一附属医院乳腺胸部肿瘤外科,海口570102

出　　处：《安徽医科大学学报》2021年第4期628-631,共4页Acta Universitatis Medicinalis Anhui

基　　金：国家自然科学基金(编号:81660550);海南医学院科研培育基金(编号:HYPY201911)。

摘　　要：目的探讨DNA损伤修复基因XPG rs873601位点多态与肺癌铂类药物化疗疗效及预后的关联,为肺癌患者的精准治疗提供依据。方法选择经病理学确诊的120例以铂类为基础化疗的肺癌患者作为研究对象,获得知情同意后,取外周静脉血2~3 ml,提取DNA,采用质谱法检测XPG基因rs873601位点的多态性;采用WHO实体瘤疗效评价标准对患者的化疗疗效进行判定,通过电话随访等方式获得患者的生存情况。结果120例肺癌患者中,XPG基因rs873601位点3种基因型频率分布为53例(44.2%)、61例(50.8%)和6例(5%),符合Hardy-Weinberg遗传平衡定律(χ^(2)=4.81)。总的化疗有效率为32.5%,携带XPG基因rs873601 AA基因型患者的化疗有效率最高,达43.4%,而GG基因型最低,仅16.7%,不同基因型间疗效差异有统计学意义(χ^(2)=7.747,P=0.046);120例肺癌患者1年生存率为73.2%,5年生存率为20.8%,携带XPG基因rs873601 AA基因型生存率最低,1年生存率60.4%,5年生存率18.3%,不同基因型间生存率差异无统计学意义(χ^(2)=3.300,P=0.348)。结论XPG rs873601位点多态性可能与肺癌铂类化疗疗效相关联,可以作为预测肺癌化疗有效性的标志物之一。Objective To investigate the relationship between DNA damage repair gene XPG rs873601 polymorphism and the efficacy and prognosis of chemotherapy for lung cancer platinum drugs,so as to provide a scientific theoretical basis for accurate treatment of lung cancer patients.Methods 120 patients with lung cancer who received platinum-based chemotherapy were confirmed by pathology.After informed consent was obtained,we extracted peripheral blood DNA from 2-3 ml of peripheral venous bloodand detected the polymorphism of XPG rs873601 locus by mass spectrometry.WHO's solid tumor efficacy evaluation criteria were used to determine the efficacy of chemotherapy for patients,and the survival of patients was obtained by telephone follow-up and other methods.Results Among 120 patients with lung cancer,the frequency distribution of the three genotypes of the XPSrs873601 was 53(44.2%),61(50.8%),and 6(5%),which complied with the Hardy-Weinberg law of genetic balance(χ^(2)=4.81).The total effective rate of chemotherapy was 32.5%.Patients with the XPG gene rs873601 AA genotype had the highest effective rate of chemotherapy,reaching 43.4%,while the GG genotype had the lowest,only 16.7%.The difference in efficacy between different genotypes was statistically significant(χ^(2)=7.747,P=0.046).The total one-year survival rate of 120 lung cancer patients was 73.2%,the five-years survival rate was 20.8%,and the XPG gene rs873601 AA genotype had the lowest survival rate,the one-year survival rate was 60.4%,the five-years survival rate was 18.3%,and there was no statistically significant difference in survival rates between SNP(χ^(2)=3.300,P=0.348).Conclusion XPG rs873601polymorphism is associated with the efficacy of platinum-based chemotherapy for lung cancer,and it can be used as one of the markers for predicting the effectiveness of chemotherapy for lung cancer.

关 键 词：XPG 肺癌 铂类化疗药 单核苷酸多态性 

分 类 号：R734[医药卫生—肿瘤]